Non-surgical treatments of primary, non-melanoma eyelid malignancies: A review

Clinical and Experimental Ophthalmology

Volumn 39, Issue 1, 2011, Pages 65-83

  Murchison, Ann P ^a   Walrath, Joseph D ^b   Washington, Carl V ^c  

^a WILLS EYE HOSPITAL   (United States)

^b Epidemiology and Biostatistics   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Malignancy; Skin cancer; Treatment

Indexed keywords

ALPHA2B INTERFERON; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BEXAROTENE; BLEOMYCIN; CANDIDA ANTIGEN; CARBON DIOXIDE; CELECOXIB; CIDOFOVIR; CYCLOOXYGENASE 2 INHIBITOR; DEOXYRIBONUCLEASE (PYRIMIDINE DIMER); DICLOFENAC; FLUOROURACIL; GLYCOLIC ACID; HYALURONIC ACID; IMIQUIMOD; INTERLEUKIN 2; JESSNER SOLUTION; LACTIC ACID; LIQUID NITROGEN; NEWCASTLE DISEASE VACCINE; PHENOL; RETINOID; SALICYLIC ACID; TAZAROTENE; TRICHLOROACETIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BASAL CELL CARCINOMA; BENIGN TUMOR; BOWEN DISEASE; CANCER RADIOTHERAPY; CARCINOGENESIS; CONJUNCTIVA DISEASE; CONSERVATIVE TREATMENT; CRYOSURGERY; CRYOTHERAPY; CYTOMEGALOVIRUS RETINITIS; DIET SUPPLEMENTATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG PENETRATION; ELECTROPORATION; ENDOPHTHALMITIS; ERYTHEMA; EXTERNAL BEAM RADIOTHERAPY; EYELID CANCER; EYELID DISEASE; FLU LIKE SYNDROME; FREEZING; HEAD AND NECK CARCINOMA; HERBAL MEDICINE; HERPES SIMPLEX; HIGH RISK PATIENT; HUMAN; HYPERPIGMENTATION; IMMUNOTHERAPY; KERATITIS; KERATOACANTHOMA; KERATOSIS; LASER SURGERY; MEDICAL LITERATURE; MELANOMA; MYCOSIS; NEOPLASM; NONHUMAN; NONMELANOMA SKIN CANCER; PAIN; PHOTODYNAMIC THERAPY; POSTOPERATIVE CARE; PRECANCER; REVIEW; SCAR; SKIN CANCER; SKIN DISEASE; SKIN MANIFESTATION; SKIN METASTASIS; SKIN TUMOR; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; SURGICAL RISK; SURGICAL TECHNIQUE; T CELL LYMPHOMA; TREATMENT INDICATION; TREATMENT OUTCOME; VERRUCA VULGARIS; XERODERMA PIGMENTOSUM;

ADENOCARCINOMA, SEBACEOUS; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CRYOSURGERY; ELECTROCOAGULATION; EYELID NEOPLASMS; HUMANS; IMMUNOTHERAPY; LASER THERAPY; PHOTOCHEMOTHERAPY; RADIOTHERAPY; SKIN NEOPLASMS;

EID: 79851495264     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2010.02422.x     Document Type: Review

References (201)

1. Lindgren G, Larko O. Long-term follow-up of cryosurgery of basal cell carcinoma of the eyelid. J Am Acad Dermatol 1997; 36: 742-6.
2. Buschmann W. A reappraisal of cryosurgery for eyelid basal cell carcinomas. Br J Ophthalmol 2002; 86: 453-7.
3. Mazur P. Freezing of living cells: mechanisms and implications. Am J Physiol 1984; 247: C125-42.
4. Kuflik EG, Gage AA. Cryosurgical Treatment for Skin Cancer. New York: Igaku-Shoin, 1990.
5. Ascensao AC. Cryosurgery of skin cancer: basic principles. Skin Cancer 1986; 1: 10.
6. Torre D. Alternate cryogens for cryosurgery. J Dermatol Surg 1975; 1: 56-8.
7. Zacharian S. Cryosurgery for Skin Cancer and Cutaneous Disorders. St. Louis, MO: Mosby, 1985.
8. Gage AA. Cryosurgery for difficult problems in cutaneous cancer. Cutis 1975; 16: 465-70.
9. Graham GF. Cryosurgery. Clin Plast Surg 1993; 20: 131-47.
10. Torre DLR, Kuflik EG. Practical Cutaneous Cryosurgery. Norwalk, CT: Appleton & Lange, 1998.
11. Lubritz RR. Cryosurgical management of multiple skin carcinomas. J Dermatol Surg Oncol 1977; 3: 414-6.
12. Graham GF, Stewart R. Cryosurgery for unusual cutaneous neoplasms. J Dermatol Surg Oncol 1977; 3: 437-42.
13. Bohler-Sommeregger K, Schuller-Petrovic S, Neumann R, Muller E. Cryosurgery of lentigo maligna. Plast Reconstr Surg 1992; 90: 436-40; discussion 41-4.
14. Collins P, Rogers S, Goggin M, Manning W. Cryotherapy for lentigo maligna. Clin Exp Dermatol 1991; 16: 433-5.
15. Lubritz RR, Smolewski SA. Cryosurgery cure rate of actinic keratoses. J Am Acad Dermatol 1982; 7: 631-2.
16. Chiarello SE. Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison. Dermatol Surg 2000; 26: 728-32.
17. Kuflik EG. Cryosurgery for skin cancer: 30-year experience and cure rates. Dermatol Surg 2004; 30: 297-300.
18. Fraunfelder FT, Zacarian SA, Limmer BL, Wingfield D. Cryosurgery for malignancies of the eyelid. Ophthalmology 1980; 87: 461-5.
19. Fraunfelder FT, Zacarian SA, Wingfield DL, Limmer BL. Results of cryotherapy for eyelid malignancies. Am J Ophthalmol 1984; 97: 184-8.
20. Kuflik EG. Two primary basal-cell carcinomas on an eyelid. J Dermatol Surg Oncol 1983; 9: 439-41.
21. Kuflik EG. Cryosurgery for basal-cell carcinomas on and around eyelids. J Dermatol Surg Oncol 1978; 4: 911-3.
22. Kuflik EG. Cryosurgery for carcinoma of the eyelids: a 12-year experience. J Dermatol Surg Oncol 1985; 11: 243-6.
23. Biro L, Price E. Cryosurgical management of basal cell carcinoma of the eyelid: a 10-year experience. J Am Acad Dermatol 1990; 23: 316-7.
24. Zacarian SA. Cancer of the eyelid - a cryosurgical approach. Ann Ophthalmol 1972; 4: 473-80.
25. Fraunfelder FT, Wallace TR, Farris HE etal. The role of cryosurgery in external ocular and periocular disease. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 1977; 83: 713-24.
26. Boughton RS, Spencer SK. Electrosurgical fundamentals. J Am Acad Dermatol 1987; 16: 862-7.
27. Bennett R. Fundamentals of Cutaneous Surgery. St. Louis, MO: Mosby, 1988.
28. Kopf AW, Bart RS, Schrager D, Lazar M, Popkin GL. Curettage-electrodesiccation treatment of basal cell carcinomas. Arch Dermatol 1977; 113: 439-43.
29. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989; 15: 315-28.
30. Werlinger KD, Upton G, Moore AY. Recurrence rates of primary nonmelanoma skin cancers treated by surgical excision compared to electrodesiccation-curettage in a private dermatological practice. Dermatol Surg 2002; 28: 1138-42; discussion 42.
31. Sheridan AT, Dawber RP. Curettage, electrosurgery and skin cancer. Australas J Dermatol 2000; 41: 19-30.
32. Silverman MK, Kopf AW, Gladstein AH, Bart RS, Grin CM, Levenstein MJ. Recurrence rates of treated basal cell carcinomas. Part 4: X-ray therapy. J Dermatol Surg Oncol 1992; 18: 549-54.
33. Soon SL, Washington CV. Electrosurgery, electrocoagulation, electrofulguration, electrodessication, electrosection, eletrocautery. In: Robinson JK, Hanke CW, Sengelmann RD, Siegel DM, ed. Surgery of the skin: Procedural dermatology. Philadelphia, PA: Mosby, 2005; 177-90.
34. Zagrodnik B, Kempf W, Seifert B etal. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2. Cancer 2003; 98: 2708-14.
35. Goldman GD. Squamous cell cancer: a practical approach. Semin Cutan Med Surg 1998; 17: 80-95.
36. Schlienger P, Brunin F, Desjardins L, Laurent M, Haye C, Vilcoq JR. External radiotherapy for carcinoma of the eyelid: report of 850 cases treated. Int J Radiat Oncol Biol Phys 1996; 34: 277-87.
37. Fitzpatrick PJ, Thompson GA, Easterbrook WM, Gallie BL, Payne DG. Basal and squamous cell carcinoma of the eyelids and their treatment by radiotherapy. Int J Radiat Oncol Biol Phys 1984; 10: 449-54.
38. Lederman M. Radiation treatment of cancer of the eyelids. Br J Ophthalmol 1976; 60: 794-805.
39. Older JJ, Quickert MH, Beard C. Surgical removal of basal cell carcinoma of the eyelids utilizing frozen section control. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 1975; 79: 658-63.
40. Bertelsen K, Gadeberg C. Carcinoma of the eyelid. Acta Radiol Oncol Radiat Phys Biol 1978; 17: 58-64.
41. Daly NJ, de Lafontan B, Combes PF. Results of the treatment of 165 lid carcinomas by iridium wire implant. Int J Radiat Oncol Biol Phys 1984; 10: 455-9.
42. Veness MJ. Treatment recommendations in patients diagnosed with high-risk cutaneous squamous cell carcinoma. Australas Radiol 2005; 49: 365-76.
43. Veness M, Richards S. Role of modern radiotherapy in treating skin cancer. Australas J Dermatol 2003; 44: 159-66; quiz 67-8.
44. Petsuksiri J, Frank SJ, Garden AS etal. Outcomes after radiotherapy for squamous cell carcinoma of the eyelid. Cancer 2008; 112: 111-8.
45. Hsu A, Frank SJ, Ballo MT etal. Postoperative adjuvant external-beam radiation therapy for cancers of the eyelid and conjunctiva. Ophthal Plast Reconstr Surg 2008; 24: 444-9.
46. Rodriguez JM, Deutsch GP. The treatment of periocular basal cell carcinomas by radiotherapy. Br J Ophthalmol 1992; 76: 195-7.
47. Parsons JT, Bova FJ, Fitzgerald CR, Mendenhall WM, Million RR. Severe dry-eye syndrome following external beam irradiation. Int J Radiat Oncol Biol Phys 1994; 30: 775-80.
48. Parsons JT, Bova FJ, Fitzgerald CR, Mendenhall WM, Million RR. Radiation retinopathy after external-beam irradiation: analysis of time-dose factors. Int J Radiat Oncol Biol Phys 1994; 30: 765-73.
49. Parsons JT, Bova FJ, Fitzgerald CR, Mendenhall WM, Million RR. Radiation optic neuropathy after megavoltage external-beam irradiation: analysis of time-dose factors. Int J Radiat Oncol Biol Phys 1994; 30: 755-63.
50. Parsons JT, Bova FJ, Mendenhall WM, Million RR, Fitzgerald CR. Response of the normal eye to high dose radiotherapy. Oncology (Huntingt) 1996; 10: 837-47; discussion 47-8, 51-2.
51. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 1992; 14: 275-92.
52. Svanberg K, Andersson T, Killander D etal. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-amino levulinic acid sensitization and laser irradiation. Br J Dermatol 1994; 130: 743-51.
53. Brancaleon L, Moseley H. Laser and non-laser light sources for photodynamic therapy. Lasers Med Sci 2002; 17: 173-86.
54. Piacquadio DJ, Chen DM, Farber HF etal. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol 2004; 140: 41-6.
55. Tschen EH, Wong DS, Pariser DM, Dunlap FE, Houlihan A, Ferdon MB. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol 2006; 155: 1262-9.
56. Tarstedt M, Rosdahl I, Berne B, Svanberg K, Wennberg AM. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol 2005; 85: 424-8.
57. Freeman M, Vinciullo C, Francis D etal. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat 2003; 14: 99-106.
58. Pariser DM, Lowe NJ, Stewart DM etal. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003; 48: 227-32.
59. Blume JE, Oseroff AR. Aminolevulinic acid photodynamic therapy for skin cancers. Dermatol Clin 2007; 25: 5-14.
60. Braathen LR, Szeimies RM, Basset-Seguin N etal. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol 2007; 56: 125-43.
61. Morton CA, Whitehurst C, Mccoll JH, Moore JV, MacKie RM. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol 2001; 137: 319-24.
62. Clark C, Bryden A, Dawe R, Moseley H, Ferguson J, Ibbotson SH. Topical 5-aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources. Photodermatol Photoimmunol Photomed 2003; 19: 134-41.
63. Basset-Seguin N, Ibbotson SH, Emtestam L etal. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5year randomized trial. Eur J Dermatol 2008; 18: 547-53.
64. Morton CA. Methyl aminolevulinate: actinic keratoses and Bowen's disease. Dermatol Clin 2007; 25: 81-7.
65. Wang I, Bauer B, Andersson-Engels S, Svanberg S, Svanberg K. Photodynamic therapy utilising topical delta-aminolevulinic acid in non-melanoma skin malignancies of the eyelid and the periocular skin. Acta Ophthalmol Scand 1999; 77: 182-8.
66. Puccioni M, Santoro N, Giansanti F etal. Photodynamic therapy using methyl aminolevulinate acid in eyelid basal cell carcinoma: a 5-year follow-up study. Ophthal Plast Reconstr Surg 2009; 25: 115-8.
67. Kotimaki J. Photodynamic therapy of eyelid basal cell carcinoma. J Eur Acad Dermatol Venereol 2009; 23: 1083-7.
68. Togsverd-Bo K, Haedersdal M, Wulf HC. Photodynamic therapy for tumors on the eyelid margins. Arch Dermatol 2009; 145: 944-7.
69. Hoerauf H, Huttmann G, Diddens H, Thiele B, Laqua H. [Photodynamic therapy of eyelid basalioma after topical administration of delta-aminolevulinic acid]. Ophthalmologe 1994; 91: 824-9.
70. Hintschich C, Feyh J, Beyer-Machule C, Riedel K, Ludwig K. Photodynamic laser therapy of basal-cell carcinoma of the lid. Ger J Ophthalmol 1993; 2: 212-7.
71. Morton C, Horn M, Leman J etal. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch Dermatol 2006; 142: 729-35.
72. Morton CA, Whitehurst C, Moseley H, Mccoll JH, Moore JV, Mackie RM. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol 1996; 135: 766-71.
73. Salim A, Leman JA, Mccoll JH, Chapman R, Morton CA. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br J Dermatol 2003; 148: 539-43.
74. Fink-Puches R, Soyer HP, Hofer A, Kerl H, Wolf P. Long-term follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical delta-aminolevulinic acid photodynamic therapy. Arch Dermatol 1998; 134: 821-6.
75. Walsh JT Jr, Flotte TJ, Deutsch TF. Er:YAG laser ablation of tissue: effect of pulse duration and tissue type on thermal damage. Lasers Surg Med 1989; 9: 314-26.
76. 2 laser resurfacing. Semin Cutan Med Surg 1996; 15: 189-93.
77. Alster TS, Lupton JR. An overview of cutaneous laser resurfacing. Clin Plast Surg 2001; 28: 37-52.
78. Jiang SB, Levine VJ, Nehal KS, Baldassano M, Kamino H, Ashinoff RA. Er:YAG laser for the treatment of actinic keratoses. Dermatol Surg 2000; 26: 437-40.
79. Iyer S, Friedli A, Bowes L, Kricorian G, Fitzpatrick RE. Full face laser resurfacing: therapy and prophylaxis for actinic keratoses and non-melanoma skin cancer. Lasers Surg Med 2004; 34: 114-9.
80. Massey RA, Eliezri YD. A case report of laser resurfacing as a skin cancer prophylaxis. Dermatol Surg 1999; 25: 513-6.
81. Trimas SJ, Ellis DA, Metz RD. The carbon dioxide laser. An alternative for the treatment of actinically damaged skin. Dermatol Surg 1997; 23: 885-9.
82. Hantash BM, Stewart DB, Cooper ZA, Rehmus WE, Koch RJ, Swetter SM. Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch Dermatol 2006; 142: 976-82.
83. Iyer S, Bowes L, Kricorian G, Friedli A, Fitzpatrick RE. Treatment of basal cell carcinoma with the pulsed carbon dioxide laser: a retrospective analysis. Dermatol Surg 2004; 30: 1214-8.
84. Humphreys TR, Malhotra R, Scharf MJ, Marcus SM, Starkus L, Calegari K. Treatment of superficial basal cell carcinoma and squamous cell carcinoma in situ with a high-energy pulsed carbon dioxide laser. Arch Dermatol 1998; 134: 1247-52.
85. Nanni CA, Alster TS. Complications of cutaneous laser surgery. A review. Dermatol Surg 1998; 24: 209-19.
86. 2 laser. Lasers Surg Med 1999; 24: 122-7.
87. 2 laser resurfacing: four cases. Lasers Surg Med 2009; 41: 179-84.
88. Lawrence N, Cox SE, Cockerell CJ, Freeman RG, Cruz PD Jr. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol 1995; 131: 176-81.
89. Matarasso SL, Salman SM, Glogau RG, Rogers GS. The role of chemical peeling in the treatment of photodamaged skin. J Dermatol Surg Oncol 1990; 16: 945-54.
90. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000; 43: S6-11.
91. Woodmansee C, Pillow J, Skinner RB Jr. The role of topical immune response modifiers in skin cancer. Drugs 2006; 66: 1657-64.
92. Jo JH, Ko HC, Jang HS, Kim MB, Oh CK, Kwon KS. Infiltrative trichilemmal carcinoma treated with 5% imiquimod cream. Dermatol Surg 2005; 31: 973-6.
93. Vidal D, Matias-Guiu X, Alomar A. Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up. Arch Dermatol 2007; 143: 266-8.
94. Ross AH, Kennedy CT, Collins C, Harrad RA. The use of imiquimod in the treatment of periocular tumours. Orbit 2010; 29: 83-7.
95. Carneiro RC, de Macedo EM, Matayoshi S. Imiquimod 5% cream for the treatment of periocular Basal cell carcinoma. Ophthal Plast Reconstr Surg 2010; 26: 100-2.
96. Choontanom R, Thanos S, Busse H, Stupp T. Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1217-20.
97. Wagstaff AJ, Perry CM. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs 2007; 67: 2187-210.
98. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two Phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50: 722-33.
99. Murchison AP, Washington CV, Soloman AR, Bernardino CR. Ocular effects of imiquimod with treatment of eyelid melanoma in situ. Dermatol Surg 2007; 33: 1136-8.
100. Bassukas ID, Gamvroulia C, Zioga A, Nomikos K, Fotika C. Cryosurgery during topical imiquimod: a successful combination modality for lentigo maligna. Int J Dermatol 2008; 47: 519-21.
101. Devirgiliis V, Panasiti V, Curzio M etal. Complete remission of nodular basal cell carcinoma after combined treatment with photodynamic therapy and imiquimod 5% cream. Dermatol Online J 2008; 14:25.
102. Harting M, Vujevich J, Goldberg LH. Residual basal cell carcinoma after treatment with imiquimod: a caution on assuming complete cure. Dermatol Surg 2007; 33: 1516-9.
103. van Meurs T, van Doorn R, Kirtschig G. Recurrence of lentigo maligna after initial complete response to treatment with 5% imiquimod cream. Dermatol Surg 2007; 33: 623-6; discussion 6-7.
104. Gross K, Kircik L, Kricorian G. 5% 5-fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg 2007; 33: 433-9; discussion 40.
105. Abraham LM, Selva D, Casson R, Leibovitch I. The clinical applications of fluorouracil in ophthalmic practice. Drugs 2007; 67: 237-55.
106. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol 2009; 145: 1431-8.
107. Ceilley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol 2006; 45: 489-98.
108. Mann JR, Backlund MG, DuBois RN. Mechanisms of disease: inflammatory mediators and cancer prevention. Nat Clin Pract Oncol 2005; 2: 202-10.
109. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006; 55: 115-22.
110. Buckman SY, Gresham A, Hale P etal. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998; 19: 723-9.
111. Kandil HM, Tanner G, Smalley W, Halter S, Radhika A, Dubois RN. Cyclooxygenase-2 expression in Barrett's esophagus. Dig Dis Sci 2001; 46: 785-9.
112. Kagoura M, Toyoda M, Matsui C, Morohashi M. Immunohistochemical expression of cyclooxygenase-2 in skin cancers. J Cutan Pathol 2001; 28: 298-302.
113. Muller-Decker K, Neufang G, Berger I, Neumann M, Marks F, Furstenberger G. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci USA 2002; 99: 12483-8.
114. An KP, Athar M, Tang X etal. Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol 2002; 76: 73-80.
115. Fecker LF, Stockfleth E, Nindl I, Ulrich C, Forschner T, Eberle J. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol 2007; 156 (Suppl. 3): 25-33.
116. Friedman ES, LaNatra N, Stiller MJ. NSAIDs in dermatologic therapy: review and preview. J Cutan Med Surg 2002; 6: 449-59.
117. Nelson C, Rigel D, Smith S, Swanson N, Wolf J. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol 2004; 3: 401-7.
118. Zhan H, Zheng H. The role of topical cyclo-oxygenase-2 inhibitors in skin cancer: treatment and prevention. Am J Clin Dermatol 2007; 8: 195-200.
119. Lejeune FJ, Monnier Y, Ruegg C. Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor. Melanoma Res 2006; 16: 263-5.
120. O'Brien WM, Bagby GF. Rare adverse reactions to nonsteroidal antiinflammatory drugs. J Rheumatol 1985; 12: 13-20.
121. Zabawski EJ Jr. A review of topical and intralesional cidofovir. Dermatol Online J 2000; 6: 3.
122. Huber MA, Staib G, Pehamberger H, Scharffetter-Kochanek K. Management of refractory early-stage cutaneous T-cell lymphoma. Am J Clin Dermatol 2006; 7: 155-69.
123. Poddevin B, Orlowski S, Belehradek J Jr, Mir LM. Very high cytotoxicity of bleomycin introduced into the cytosol of cells in culture. Biochem Pharmacol 1991; 42 (Suppl.): S67-75.
124. Orlowski S, Belehradek J Jr, Paoletti C, Mir LM. Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol 1988; 37: 4727-33.
125. Mir LM, Glass LF, Sersa G etal. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 1998; 77: 2336-42.
126. Glass LF, Jaroszeski M, Gilbert R, Reintgen DS, Heller R. Intralesional bleomycin-mediated electrochemotherapy in 20 patients with basal cell carcinoma. J Am Acad Dermatol 1997; 37: 596-9.
127. Rodriguez-Cuevas S, Barroso-Bravo S, Almanza-Estrada J, Cristobal-Martinez L, Gonzalez-Rodriguez E. Electrochemotherapy in primary and metastatic skin tumors: phase II trial using intralesional bleomycin. Arch Med Res 2001; 32: 273-6.
128. Bloom DC, Goldfarb PM. The role of intratumour therapy with electroporation and bleomycin in the management of advanced squamous cell carcinoma of the head and neck. Eur J Surg Oncol 2005; 31: 1029-35.
129. Glass LF, Fenske NA, Jaroszeski M etal. Bleomycin-mediated electrochemotherapy of basal cell carcinoma. J Am Acad Dermatol 1996; 34: 82-6.
130. Orenberg EK, Miller BH, Greenway HT etal. The effect of intralesional 5-fluorouracil therapeutic implant (MPI 5003) for treatment of basal cell carcinoma. J Am Acad Dermatol 1992; 27: 723-8.
131. Miller BH, Shavin JS, Cognetta A etal. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. J Am Acad Dermatol 1997; 36: 72-7.
132. Morse LG, Kendrick C, Hooper D, Ward H, Parry E. Treatment of squamous cell carcinoma with intralesional 5-fluorouracil. Dermatol Surg 2003; 29: 1150-3; discussion 3.
133. Kraus S, Miller BH, Swinehart JM etal. Intratumoral chemotherapy with fluorouracil/epinephrine injectable gel: a nonsurgical treatment of cutaneous squamous cell carcinoma. J Am Acad Dermatol 1998; 38: 438-42.
134. Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J Jr, Mir LM. Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial. Cancer 1993; 72: 3694-700.
135. Urosevic M, Dummer R. Immunotherapy for nonmelanoma skin cancer: does it have a future? Cancer 2002; 94: 477-85.
136. Buechner S, Wernli M, Bachmann F, Harr T, Erb P. Intralesional interferon in basal cell carcinoma: how does it work? Recent Results Cancer Res 2002; 160: 246-50.
137. Ikic D, Padovan I, Pipic N etal. Interferon therapy for basal cell carcinoma and squamous cell carcinoma. Int J Clin Pharmacol Ther Toxicol 1991; 29: 342-6.
138. Chimenti S, Peris K, Di Cristofaro S, Fargnoli MC, Torlone G. Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma. Dermatology 1995; 190: 214-7.
139. Stenquist B, Wennberg AM, Gisslen H, Larko O. Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery. J Am Acad Dermatol 1992; 27: 65-9.
140. DiLorenzo PA, Goodman N, Lansville F, Markel W. Regional and intralesional treatment of invasive basal cell carcinoma with interferon alfa-n2b. J Am Acad Dermatol 1994; 31: 109-11.
141. Edwards L, Berman B, Rapini RP etal. Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy. Arch Dermatol 1992; 128: 1486-9.
142. Kim KH, Yavel RM, Gross VL, Brody N. Intralesional interferon alpha-2b in the treatment of basal cell carcinoma and squamous cell carcinoma: revisited. Dermatol Surg 2004; 30: 116-20.
143. Rogalski C, Dummer R, Burg G. Immunomodulators in the treatment of cutaneous lymphoma. J Eur Acad Dermatol Venereol 1999; 13: 83-90.
144. Mihara M, Nakayama H, Nakamura K, Morimura T, Hagari Y, Shimao S. Histologic changes in superficial basal cell epithelioma and Bowen's disease by intralesional injection of recombinant interleukin 2: recombinant interleukin 2 may induce redifferentiation of malignant tumor cells in vivo. Arch Dermatol 1990; 126: 1107.
145. Kaplan B, Moy RL. Effect of perilesional injections of PEG-interleukin-2 on basal cell carcinoma. Dermatol Surg 2000; 26: 1037-40.
146. Whiteside TL, Letessier E, Hirabayashi H etal. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res 1993; 53: 5654-62.
147. Holtermann OA, Papermaster B, Rosner D, Milgrom H, Klein E. Regression of cutaneous neoplasms following delayed-type hypersensitivity challenge reactions to microbial antigens or lymphokines. J Med 1975; 6: 157-68.
148. Aftergut K, Curry M, Cohen J. Candida antigen in the treatment of basal cell carcinoma. Dermatol Surg 2005; 31: 16-8.
149. Greenway HT, Cornell RC, Tanner DJ, Peets E, Bordin GM, Nagi C. Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol 1986; 15: 437-43.
150. Cornell RC, Greenway HT, Tucker SB etal. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 1990; 23: 694-700.
151. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-91.
152. DiGiovanna JJ. Retinoid chemoprevention in patients at high risk for skin cancer. Med Pediatr Oncol 2001; 36: 564-7.
153. DiGiovanna JJ. Retinoids for the future: oncology. J Am Acad Dermatol 1992; 27: S34-7.
154. Niles RM. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. Nutrition 2000; 16: 1084-9.
155. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1: 181-93.
156. Vandeghinste N, De Bersaques J, Geerts ML, Kint A. Acitretin as cancer chemoprophylaxis in a renal transplant recipient. Dermatology 1992; 185: 307-8.
157. McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5years of experience using low-dose acitretin. Br J Dermatol 1999; 140: 656-60.
158. de Sevaux RG, Smit JV, de Jong EM, van de Kerkhof PC, Hoitsma AJ. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin. J Am Acad Dermatol 2003; 49: 407-12.
159. Bavinck JN, Tieben LM, Van der Woude FJ etal. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 1933-8.
160. Cumurcu T, Sezer E, Kilic R, Bulut Y. Comparison of dose-related ocular side effects during systemic isotretinoin administration. Eur J Ophthalmol 2009; 19: 196-200.
161. Blackman HJ, Peck GL, Olsen TG, Bergsma DR. Blepharoconjunctivitis: a side effect of 13-cis-retinoic acid therapy for dermatologic diseases. Ophthalmology 1979; 86: 753-9.
162. Gross EG, Helfgott MA. Retinoids and the eye. Dermatol Clin 1992; 10: 521-31.
163. Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications: recognition and management. Drugs 2007; 67: 75-93.
164. Decensi A, Torrisi R, Polizzi A etal. Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface. J Natl Cancer Inst 1994; 86: 105-10.
165. Karalezli A, Borazan M, Altinors DD, Dursun R, Kiyici H, Akova YA. Conjunctival impression cytology, ocular surface, and tear-film changes in patients treated with systemic isotretinoin. Cornea 2009; 28: 46-50.
166. De Graaf YG, Euvrard S, Bouwes Bavinck JN. Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol Surg 2004; 30: 656-61.
167. Fraunfelder FT, LaBraico JM, Meyer SM. Adverse ocular reactions possibly associated with isotretinoin. Am J Ophthalmol 1985; 100: 534-7.
168. Batliwalla FM, Bateman BA, Serrano D etal. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med 1998; 4: 783-94.
169. Goel R, Swanlund D, Coad J, Paciotti GF, Bischof JC. TNF-alpha-based accentuation in cryoinjury - dose, delivery, and response. Mol Cancer Ther 2007; 6: 2039-47.
170. Paciotti GF, Myer L, Weinreich D etal. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv 2004; 11: 169-83.
171. Chao BH, He X, Bischof JC. Pre-treatment inflammation induced by TNF-alpha augments cryosurgical injury on human prostate cancer. Cryobiology 2004; 49: 10-27.
172. Subongkot S, Frame D, Leslie W, Drajer D. Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment. Pharmacotherapy 2003; 23: 9-28.
173. Wilgus TA, Breza TS Jr, Tober KL, Oberyszyn TM. Treatment with 5-fluorouracil and celecoxib displays synergistic regression of ultraviolet light B-induced skin tumors. J Invest Dermatol 2004; 122: 1488-94.
174. Akita Y, Kozaki K, Nakagawa A etal. Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity. Br J Dermatol 2004; 151: 472-80.
175. Fuller CJ, Faulkner H, Bendich A, Parker RS, Roe DA. Effect of beta-carotene supplementation on photosuppression of delayed-type hypersensitivity in normal young men. Am J Clin Nutr 1992; 56: 684-90.
176. van Dam RM, Huang Z, Giovannucci E etal. Diet and basal cell carcinoma of the skin in a prospective cohort of men. Am J Clin Nutr 2000; 71: 135-41.
177. Greenberg ER, Baron JA, Stukel TA etal. A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. The Skin Cancer Prevention Study Group. N Engl J Med 1990; 323: 789-95.
178. Stahl W, Heinrich U, Jungmann H, Sies H, Tronnier H. Carotenoids and carotenoids plus vitamin E protect against ultraviolet light-induced erythema in humans. Am J Clin Nutr 2000; 71: 795-8.
179. Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC. Current use and future potential role of retinoids in dermatology. Drugs 1997; 53: 358-88.
180. Lippman SM, Kessler JF, Meyskens FL Jr. Retinoids as preventive and therapeutic anticancer agents (Part II). Cancer Treat Rep 1987; 71: 493-515.
181. Tangrea JA, Edwards BK, Taylor PR etal. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group. J Natl Cancer Inst 1992; 84: 328-32.
182. Levine N, Moon TE, Cartmel B etal. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 1997; 6: 957-61.
183. Shindo Y, Witt E, Han D, Packer L. Dose-response effects of acute ultraviolet irradiation on antioxidants and molecular markers of oxidation in murine epidermis and dermis. J Invest Dermatol 1994; 102: 470-5.
184. Darr D, Combs S, Dunston S, Manning T, Pinnell S. Topical vitamin C protects porcine skin from ultraviolet radiation-induced damage. Br J Dermatol 1992; 127: 247-53.
185. Bissett DL, Chatterjee R, Hannon DP. Photoprotective effect of superoxide-scavenging antioxidants against ultraviolet radiation-induced chronic skin damage in the hairless mouse. Photodermatol Photoimmunol Photomed 1990; 7: 56-62.
186. Eberlein-Konig B, Placzek M, Przybilla B. Protective effect against sunburn of combined systemic ascorbic acid (vitamin C) and d-alpha-tocopherol (vitamin E). J Am Acad Dermatol 1998; 38: 45-8.
187. Fuchs J, Kern H. Modulation of UV-light-induced skin inflammation by d-alpha-tocopherol and L-ascorbic acid: a clinical study using solar simulated radiation. Free Radic Biol Med 1998; 25: 1006-12.
188. Dreher F, Gabard B, Schwindt DA, Maibach HI. Topical melatonin in combination with vitamins E and C protects skin from ultraviolet-induced erythema: a human study in vivo. Br J Dermatol 1998; 139: 332-9.
189. Bialy TL, Rothe MJ, Grant-Kels JM. Dietary factors in the prevention and treatment of nonmelanoma skin cancer and melanoma. Dermatol Surg 2002; 28: 1143-52.
190. Werninghaus K, Meydani M, Bhawan J, Margolis R, Blumberg JB, Gilchrest BA. Evaluation of the photoprotective effect of oral vitamin E supplementation. Arch Dermatol 1994; 130: 1257-61.
191. Mahabir S, Frenkel K, Brady MS etal. Randomized, placebo-controlled pilot trial of the effects of alpha-tocopherol supplementation on levels of autoantibodies against 5-hydroxymethyl-2-deoxyuridine in melanoma patients. Melanoma Res 2004; 14: 49-56.
192. Buettner GR. The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch Biochem Biophys 1993; 300: 535-43.
193. Clark LC, Combs GF Jr, Turnbull BW etal. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996; 276: 1957-63.
194. Katiyar SK, Ahmad N, Mukhtar H. Green tea and skin. Arch Dermatol 2000; 136: 989-94.
195. Mukhtar H, Ahmad N. Green tea in chemoprevention of cancer. Toxicol Sci 1999; 52: 111-7.
196. Katiyar SK, Matsui MS, Elmets CA, Mukhtar H. Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea reduces UVB-induced inflammatory responses and infiltration of leukocytes in human skin. Photochem Photobiol 1999; 69: 148-53.
197. Hibatallah J, Carduner C, Poelman MC. In-vivo and in-vitro assessment of the free-radical-scavenger activity of Ginkgo flavone glycosides at high concentration. J Pharm Pharmacol 1999; 51: 1435-40.
198. Demidov LV, Manziuk LV, Kharkevitch GY, Pirogova NA, Artamonova EV. Adjuvant fermented wheat germ extract (Avemar) nutraceutical improves survival of high-risk skin melanoma patients: a randomized, pilot, phase II clinical study with a 7-year follow-up. Cancer Biother Radiopharm 2008; 23: 477-82.
199. Yan L, Yee JA, Li D, McGuire MH, Thompson LU. Dietary flaxseed supplementation and experimental metastasis of melanoma cells in mice. Cancer Lett 1998; 124: 181-6.
200. Morton CA. Non-surgical treatment of skin cancer. Australas J Dermatol 2005; 46 (Suppl. 3): S5-7; discussion S23-5.
201. Cafardi JA, Elmets CA. T4 endonuclease V: review and application to dermatology. Expert Opin Biol Ther 2008; 8: 829-38.